Drug Addiction - Pipeline Review, H2 2018

Drug Addiction - Pipeline Review, H2 2018


  • Products Id :- GMDHC10604IDB
  • |
  • Pages: 171
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Drug Addiction-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction-Pipeline Review, H2 2018, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 7, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 4 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 5

Drug Addiction-Overview 6

Drug Addiction-Therapeutics Development 7

Drug Addiction-Therapeutics Assessment 17

Drug Addiction-Companies Involved in Therapeutics Development 28

Drug Addiction-Drug Profiles 39

Drug Addiction-Dormant Projects 148

Drug Addiction-Discontinued Products 153

Drug Addiction-Product Development Milestones 154

Appendix 163

List of Figures

Number of Products under Development for Drug Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Drug Addiction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Drug Addiction-Pipeline by Addex Therapeutics Ltd, H2 2018

Drug Addiction-Pipeline by Aelis Farma SAS, H2 2018

Drug Addiction-Pipeline by Aphios Corp, H2 2018

Drug Addiction-Pipeline by BioCorRx Inc, H2 2018

Drug Addiction-Pipeline by Charleston Laboratories Inc, H2 2018

Drug Addiction-Pipeline by Chiesi Farmaceutici SpA, H2 2018

Drug Addiction-Pipeline by Consegna Pharma Inc, H2 2018

Drug Addiction-Pipeline by Curemark LLC, H2 2018

Drug Addiction-Pipeline by Egalet Corp, H2 2018

Drug Addiction-Pipeline by Embera NeuroTherapeutics Inc, H2 2018

Drug Addiction-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Drug Addiction-Pipeline by Heptares Therapeutics Ltd, H2 2018

Drug Addiction-Pipeline by IMV Inc, H2 2018

Drug Addiction-Pipeline by InterveXion Therapeutics LLC, H2 2018

Drug Addiction-Pipeline by Intra-Cellular Therapies Inc, H2 2018

Drug Addiction-Pipeline by Johnson & Johnson, H2 2018

Drug Addiction-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Drug Addiction-Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018

Drug Addiction-Pipeline by Omeros Corp, H2 2018

Drug Addiction-Pipeline by Orexigen Therapeutics Inc, H2 2018

Drug Addiction-Pipeline by Ovid Therapeutics Inc, H2 2018

Drug Addiction-Pipeline by P2D Inc, H2 2018

Drug Addiction-Pipeline by Saniona AB, H2 2018

Drug Addiction-Pipeline by SpringWorks Therapeutics LLC, H2 2018

Drug Addiction-Pipeline by Zynerba Pharmaceuticals Inc, H2 2018

Drug Addiction-Dormant Projects, H2 2018

Drug Addiction-Dormant Projects, H2 2018 (Contd..1), H2 2018

Drug Addiction-Dormant Projects, H2 2018 (Contd..2), H2 2018

Drug Addiction-Dormant Projects, H2 2018 (Contd..3), H2 2018

Drug Addiction-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Addex Therapeutics Ltd

Aelis Farma SAS

Aphios Corp

BioCorRx Inc

Charleston Laboratories Inc

Chiesi Farmaceutici SpA

Consegna Pharma Inc

Curemark LLC

Egalet Corp

Embera NeuroTherapeutics Inc

F. Hoffmann-La Roche Ltd

Heptares Therapeutics Ltd

IMV Inc

InterveXion Therapeutics LLC

Intra-Cellular Therapies Inc

Johnson & Johnson

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Omeros Corp

Orexigen Therapeutics Inc

Ovid Therapeutics Inc

P2D Inc

Saniona AB

SpringWorks Therapeutics LLC

Zynerba Pharmaceuticals Inc

Drug Addiction Therapeutic Products under Development, Key Players in Drug Addiction Therapeutics, Drug Addiction Pipeline Overview, Drug Addiction Pipeline, Drug Addiction Pipeline Assessment

select a license
Single User License
USD 2000 INR 142660
Site License
USD 4000 INR 285320
Corporate User License
USD 6000 INR 427980

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com